FDA approval of AstraZeneca’s Imjudo comes less than three weeks after the antibody won its first approval in liver cancer. Both regulatory decisions cover use of the drug in combination with another AstraZeneca immunotherapy, Imfinzi.
In a Thursday blog post, officials shared that the app’s “risk threshold” had been lowered to account for exposure to people when they are most infectious. The update was supposed to take place when the app was launched in late September.
Patient expectations continue to evolve, and healthcare practices that fail to adapt risk more than just revenue—they risk losing trust.
Through its app, London-based Echo, which was founded in 2015, offers prescription fulfillment and reminders to take medications.
Through the collaboration, FundamentalVR and Mayo Clinic will jointly develop surgical VR simulation and education products with an initial focus on general surgery. FundamentalVR also revealed a $1.4 million investment from Tern.
Longitude Capital leads round worth £25 million, which KaNDy will use to advance its non-hormonal menopause drug into Phase IIb clinical trial this year.
The Royal College of General Practitioners, a membership body for family doctors in the UK and overseas, said it is "dubious" of the London startup's claims, noting that "[n]o app or algorithm will be able to do what a GP does."
The ongoing nursing shortage facilitates high turnover rates since nurses know they won’t have difficulties finding new jobs. In order to retain and attract staff, it’s in a facility’s best interest to understand what nurses want.
Founded by surgeons Axel Sylvan and Tom Harte, London-based myrecovery is an app that helps orthopedic surgery patients communicate with their surgeon and gain advice about their recovery process.
Effective immediately, Dr. Brian Donley, an orthopedic surgeon, will take the reins as CEO of Cleveland Clinic London. The six-story, 200-bed hospital is scheduled to open in 2020.
Society likes to predict artificial intelligence coming to healthcare in the form of all-knowing robot doctors. But two companies — Avaamo and Saberr — are utilizing the technology in a simpler form. Their AI-powered chatbots are built to assist with referral management, team building and more.
The study will seek to determine whether Owlstone Medical's breath biospy tool can match the right patient for the right treatment and to assess the treatment effects of a novel drug for COPD.
FASENRA® (benralizumab) injection, for subcutaneous use, 30 mg is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). FASENRA provides a treatment option for HCPs to consider when managing this challenging disease.
An enormous ransomware attack has impacted organizations across the globe, including the National Health Service. U.K. hospitals resorted to diverting patients and using pen and paper for documentation.
A new Frost & Sullivan report predicts biometrics will be a mainstream feature of cars by 2025 from fatigue alerts to preventing drivers from nodding off.
BioBeats makes apps that apply artificial intelligence in the cloud, looking for what CEO David Plans called "instances of well-being."
AliveCor Founder and CMO Dr. Dave Albert said that this opens the door to the NHS buying AliveCor devices for all 2 million atrial fibrillation patients in England "to save money and lives by preventing strokes."
An upcoming randomized controlled trial of BioBeats' stress assessment app will have around 700 corporate users and the trial will follow a cluster randomised controlled trial design, according to co-founder Dr David Plans.